AustralieFrV1, PubMed, Corpus, bibRecord, 002D29

Recurrent venous thromboembolism in anticoagulated patients with cancer: management and short-term prognosis.

Identifieur interne : 002D29 ( PubMed/Corpus ); précédent : 002D28; suivant : 002D30

Recurrent venous thromboembolism in anticoagulated patients with cancer: management and short-term prognosis.

Auteurs : S. Schulman ; M. Zondag ; L. Linkins ; S. Pasca ; Y W Cheung ; M. De Sancho ; A. Gallus ; R. Lecumberri ; S. Molnar ; W. Ageno ; G. Le Gal ; A. Falanga ; E. Huleg Rdh ; S. Ranta ; P. Kamphuisen ; P. Debourdeau ; V. Rigamonti ; T L Ortel ; A. Lee

Source :

Journal of thrombosis and haemostasis : JTH [ 1538-7836 ] ; 2015.

RBID : pubmed:25851122

English descriptors

KwdEn :
- Aged, Anticoagulants (administration & dosage), Anticoagulants (adverse effects), Chi-Square Distribution, Drug Substitution, Female, Hemorrhage (chemically induced), Heparin, Low-Molecular-Weight (administration & dosage), Heparin, Low-Molecular-Weight (adverse effects), Humans, Kaplan-Meier Estimate, Male, Middle Aged, Neoplasms (blood), Neoplasms (complications), Neoplasms (mortality), Neoplasms (pathology), Proportional Hazards Models, Prospective Studies, Recurrence, Registries, Retrospective Studies, Risk Factors, Time Factors, Treatment Outcome, Venous Thromboembolism (blood), Venous Thromboembolism (diagnosis), Venous Thromboembolism (drug therapy), Venous Thromboembolism (etiology), Venous Thromboembolism (mortality), Vitamin K (antagonists & inhibitors), Warfarin (administration & dosage), Warfarin (adverse effects).
MESH :
- chemical , administration & dosage : Anticoagulants, Heparin, Low-Molecular-Weight, Warfarin.
- chemical , adverse effects : Anticoagulants, Heparin, Low-Molecular-Weight, Warfarin.
- chemical , antagonists & inhibitors : Vitamin K.
- blood : Neoplasms, Venous Thromboembolism.
- chemically induced : Hemorrhage.
- complications : Neoplasms.
- diagnosis : Venous Thromboembolism.
- drug therapy : Venous Thromboembolism.
- etiology : Venous Thromboembolism.
- mortality : Neoplasms, Venous Thromboembolism.
- pathology : Neoplasms.
- Aged, Chi-Square Distribution, Drug Substitution, Female, Humans, Kaplan-Meier Estimate, Male, Middle Aged, Proportional Hazards Models, Prospective Studies, Recurrence, Registries, Retrospective Studies, Risk Factors, Time Factors, Treatment Outcome.

Abstract

Recommendations for management of cancer-related venous thromboembolism (VTE) in patients already receiving anticoagulant therapy are based on low-quality evidence. This international registry sought to provide more information on outcomes after a breakthrough VTE in relation to anticoagulation strategies.

DOI: 10.1111/jth.12955
PubMed: 25851122

Links to Exploration step

pubmed:25851122

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Recurrent venous thromboembolism in anticoagulated patients with cancer: management and short-term prognosis.</title>
<author><name sortKey="Schulman, S" sort="Schulman, S" uniqKey="Schulman S" first="S" last="Schulman">S. Schulman</name>
<affiliation><nlm:affiliation>Department of Medicine, McMaster University, Hamilton, ON, Canada.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Zondag, M" sort="Zondag, M" uniqKey="Zondag M" first="M" last="Zondag">M. Zondag</name>
<affiliation><nlm:affiliation>Department of Medicine, McMaster University, Hamilton, ON, Canada.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Linkins, L" sort="Linkins, L" uniqKey="Linkins L" first="L" last="Linkins">L. Linkins</name>
<affiliation><nlm:affiliation>Department of Medicine, McMaster University, Hamilton, ON, Canada.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Pasca, S" sort="Pasca, S" uniqKey="Pasca S" first="S" last="Pasca">S. Pasca</name>
<affiliation><nlm:affiliation>Center for Hemorrhagic and Thrombotic Disease, University Hospital of Udine, Udine, Italy.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Cheung, Y W" sort="Cheung, Y W" uniqKey="Cheung Y" first="Y W" last="Cheung">Y W Cheung</name>
<affiliation><nlm:affiliation>Academic Medical Centre, University of Amsterdam, Amsterdam, the Netherlands.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="De Sancho, M" sort="De Sancho, M" uniqKey="De Sancho M" first="M" last="De Sancho">M. De Sancho</name>
<affiliation><nlm:affiliation>Weill Cornell Medical College, New York, NY, USA.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Gallus, A" sort="Gallus, A" uniqKey="Gallus A" first="A" last="Gallus">A. Gallus</name>
<affiliation><nlm:affiliation>Flinders University, Adelaide, SA, Australia.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Lecumberri, R" sort="Lecumberri, R" uniqKey="Lecumberri R" first="R" last="Lecumberri">R. Lecumberri</name>
<affiliation><nlm:affiliation>Hematology Service, University Clinic of Navarra, Pamplona, Spain.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Molnar, S" sort="Molnar, S" uniqKey="Molnar S" first="S" last="Molnar">S. Molnar</name>
<affiliation><nlm:affiliation>Oncology and Hematology Department, Sanatorio Allende, Cordoba, Argentina.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Ageno, W" sort="Ageno, W" uniqKey="Ageno W" first="W" last="Ageno">W. Ageno</name>
<affiliation><nlm:affiliation>Department of Clinical and Experimental Medicine, University of Insubria, Varese, Italy.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Le Gal, G" sort="Le Gal, G" uniqKey="Le Gal G" first="G" last="Le Gal">G. Le Gal</name>
<affiliation><nlm:affiliation>Department of Internal Medicine and Chest Diseases, Brest University Hospital, Brest, France.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Falanga, A" sort="Falanga, A" uniqKey="Falanga A" first="A" last="Falanga">A. Falanga</name>
<affiliation><nlm:affiliation>Department of Immunohematology and Transfusion Medicine, Hospital Papa Giovanni XXIII, Bergamo, Italy.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Huleg Rdh, E" sort="Huleg Rdh, E" uniqKey="Huleg Rdh E" first="E" last="Huleg Rdh">E. Huleg Rdh</name>
<affiliation><nlm:affiliation>Department of Hematology and Coagulation, Sahlgrenska University Hospital, Gothenburg, Sweden.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Ranta, S" sort="Ranta, S" uniqKey="Ranta S" first="S" last="Ranta">S. Ranta</name>
<affiliation><nlm:affiliation>Karolinska Institutet, Stockholm, Sweden.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Kamphuisen, P" sort="Kamphuisen, P" uniqKey="Kamphuisen P" first="P" last="Kamphuisen">P. Kamphuisen</name>
<affiliation><nlm:affiliation>Department of Vascular Medicine, University Medical Centre Groningen, University of Groningen, Groningen, the Netherlands.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Debourdeau, P" sort="Debourdeau, P" uniqKey="Debourdeau P" first="P" last="Debourdeau">P. Debourdeau</name>
<affiliation><nlm:affiliation>Oncology Department, Ste Catherine Institute, Avignon, France.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Rigamonti, V" sort="Rigamonti, V" uniqKey="Rigamonti V" first="V" last="Rigamonti">V. Rigamonti</name>
<affiliation><nlm:affiliation>Praxis Bubenberg, Bern, Switzerland.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Ortel, T L" sort="Ortel, T L" uniqKey="Ortel T" first="T L" last="Ortel">T L Ortel</name>
<affiliation><nlm:affiliation>Division of Hematology, Duke University Medical Center, Durham, NC, USA.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Lee, A" sort="Lee, A" uniqKey="Lee A" first="A" last="Lee">A. Lee</name>
<affiliation><nlm:affiliation>Diamond Health Care Centre, University of British Columbia and Vancouver Coastal Health, Vancouver, BC, Canada.</nlm:affiliation>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2015">2015</date>
<idno type="RBID">pubmed:25851122</idno>
<idno type="pmid">25851122</idno>
<idno type="doi">10.1111/jth.12955</idno>
<idno type="wicri:Area/PubMed/Corpus">002D29</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">002D29</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Recurrent venous thromboembolism in anticoagulated patients with cancer: management and short-term prognosis.</title>
<author><name sortKey="Schulman, S" sort="Schulman, S" uniqKey="Schulman S" first="S" last="Schulman">S. Schulman</name>
<affiliation><nlm:affiliation>Department of Medicine, McMaster University, Hamilton, ON, Canada.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Zondag, M" sort="Zondag, M" uniqKey="Zondag M" first="M" last="Zondag">M. Zondag</name>
<affiliation><nlm:affiliation>Department of Medicine, McMaster University, Hamilton, ON, Canada.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Linkins, L" sort="Linkins, L" uniqKey="Linkins L" first="L" last="Linkins">L. Linkins</name>
<affiliation><nlm:affiliation>Department of Medicine, McMaster University, Hamilton, ON, Canada.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Pasca, S" sort="Pasca, S" uniqKey="Pasca S" first="S" last="Pasca">S. Pasca</name>
<affiliation><nlm:affiliation>Center for Hemorrhagic and Thrombotic Disease, University Hospital of Udine, Udine, Italy.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Cheung, Y W" sort="Cheung, Y W" uniqKey="Cheung Y" first="Y W" last="Cheung">Y W Cheung</name>
<affiliation><nlm:affiliation>Academic Medical Centre, University of Amsterdam, Amsterdam, the Netherlands.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="De Sancho, M" sort="De Sancho, M" uniqKey="De Sancho M" first="M" last="De Sancho">M. De Sancho</name>
<affiliation><nlm:affiliation>Weill Cornell Medical College, New York, NY, USA.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Gallus, A" sort="Gallus, A" uniqKey="Gallus A" first="A" last="Gallus">A. Gallus</name>
<affiliation><nlm:affiliation>Flinders University, Adelaide, SA, Australia.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Lecumberri, R" sort="Lecumberri, R" uniqKey="Lecumberri R" first="R" last="Lecumberri">R. Lecumberri</name>
<affiliation><nlm:affiliation>Hematology Service, University Clinic of Navarra, Pamplona, Spain.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Molnar, S" sort="Molnar, S" uniqKey="Molnar S" first="S" last="Molnar">S. Molnar</name>
<affiliation><nlm:affiliation>Oncology and Hematology Department, Sanatorio Allende, Cordoba, Argentina.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Ageno, W" sort="Ageno, W" uniqKey="Ageno W" first="W" last="Ageno">W. Ageno</name>
<affiliation><nlm:affiliation>Department of Clinical and Experimental Medicine, University of Insubria, Varese, Italy.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Le Gal, G" sort="Le Gal, G" uniqKey="Le Gal G" first="G" last="Le Gal">G. Le Gal</name>
<affiliation><nlm:affiliation>Department of Internal Medicine and Chest Diseases, Brest University Hospital, Brest, France.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Falanga, A" sort="Falanga, A" uniqKey="Falanga A" first="A" last="Falanga">A. Falanga</name>
<affiliation><nlm:affiliation>Department of Immunohematology and Transfusion Medicine, Hospital Papa Giovanni XXIII, Bergamo, Italy.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Huleg Rdh, E" sort="Huleg Rdh, E" uniqKey="Huleg Rdh E" first="E" last="Huleg Rdh">E. Huleg Rdh</name>
<affiliation><nlm:affiliation>Department of Hematology and Coagulation, Sahlgrenska University Hospital, Gothenburg, Sweden.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Ranta, S" sort="Ranta, S" uniqKey="Ranta S" first="S" last="Ranta">S. Ranta</name>
<affiliation><nlm:affiliation>Karolinska Institutet, Stockholm, Sweden.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Kamphuisen, P" sort="Kamphuisen, P" uniqKey="Kamphuisen P" first="P" last="Kamphuisen">P. Kamphuisen</name>
<affiliation><nlm:affiliation>Department of Vascular Medicine, University Medical Centre Groningen, University of Groningen, Groningen, the Netherlands.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Debourdeau, P" sort="Debourdeau, P" uniqKey="Debourdeau P" first="P" last="Debourdeau">P. Debourdeau</name>
<affiliation><nlm:affiliation>Oncology Department, Ste Catherine Institute, Avignon, France.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Rigamonti, V" sort="Rigamonti, V" uniqKey="Rigamonti V" first="V" last="Rigamonti">V. Rigamonti</name>
<affiliation><nlm:affiliation>Praxis Bubenberg, Bern, Switzerland.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Ortel, T L" sort="Ortel, T L" uniqKey="Ortel T" first="T L" last="Ortel">T L Ortel</name>
<affiliation><nlm:affiliation>Division of Hematology, Duke University Medical Center, Durham, NC, USA.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Lee, A" sort="Lee, A" uniqKey="Lee A" first="A" last="Lee">A. Lee</name>
<affiliation><nlm:affiliation>Diamond Health Care Centre, University of British Columbia and Vancouver Coastal Health, Vancouver, BC, Canada.</nlm:affiliation>
</affiliation>
</author>
</analytic>
<series><title level="j">Journal of thrombosis and haemostasis : JTH</title>
<idno type="eISSN">1538-7836</idno>
<imprint><date when="2015" type="published">2015</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Aged</term>
<term>Anticoagulants (administration & dosage)</term>
<term>Anticoagulants (adverse effects)</term>
<term>Chi-Square Distribution</term>
<term>Drug Substitution</term>
<term>Female</term>
<term>Hemorrhage (chemically induced)</term>
<term>Heparin, Low-Molecular-Weight (administration & dosage)</term>
<term>Heparin, Low-Molecular-Weight (adverse effects)</term>
<term>Humans</term>
<term>Kaplan-Meier Estimate</term>
<term>Male</term>
<term>Middle Aged</term>
<term>Neoplasms (blood)</term>
<term>Neoplasms (complications)</term>
<term>Neoplasms (mortality)</term>
<term>Neoplasms (pathology)</term>
<term>Proportional Hazards Models</term>
<term>Prospective Studies</term>
<term>Recurrence</term>
<term>Registries</term>
<term>Retrospective Studies</term>
<term>Risk Factors</term>
<term>Time Factors</term>
<term>Treatment Outcome</term>
<term>Venous Thromboembolism (blood)</term>
<term>Venous Thromboembolism (diagnosis)</term>
<term>Venous Thromboembolism (drug therapy)</term>
<term>Venous Thromboembolism (etiology)</term>
<term>Venous Thromboembolism (mortality)</term>
<term>Vitamin K (antagonists & inhibitors)</term>
<term>Warfarin (administration & dosage)</term>
<term>Warfarin (adverse effects)</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Anticoagulants</term>
<term>Heparin, Low-Molecular-Weight</term>
<term>Warfarin</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Anticoagulants</term>
<term>Heparin, Low-Molecular-Weight</term>
<term>Warfarin</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="antagonists & inhibitors" xml:lang="en"><term>Vitamin K</term>
</keywords>
<keywords scheme="MESH" qualifier="blood" xml:lang="en"><term>Neoplasms</term>
<term>Venous Thromboembolism</term>
</keywords>
<keywords scheme="MESH" qualifier="chemically induced" xml:lang="en"><term>Hemorrhage</term>
</keywords>
<keywords scheme="MESH" qualifier="complications" xml:lang="en"><term>Neoplasms</term>
</keywords>
<keywords scheme="MESH" qualifier="diagnosis" xml:lang="en"><term>Venous Thromboembolism</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Venous Thromboembolism</term>
</keywords>
<keywords scheme="MESH" qualifier="etiology" xml:lang="en"><term>Venous Thromboembolism</term>
</keywords>
<keywords scheme="MESH" qualifier="mortality" xml:lang="en"><term>Neoplasms</term>
<term>Venous Thromboembolism</term>
</keywords>
<keywords scheme="MESH" qualifier="pathology" xml:lang="en"><term>Neoplasms</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Aged</term>
<term>Chi-Square Distribution</term>
<term>Drug Substitution</term>
<term>Female</term>
<term>Humans</term>
<term>Kaplan-Meier Estimate</term>
<term>Male</term>
<term>Middle Aged</term>
<term>Proportional Hazards Models</term>
<term>Prospective Studies</term>
<term>Recurrence</term>
<term>Registries</term>
<term>Retrospective Studies</term>
<term>Risk Factors</term>
<term>Time Factors</term>
<term>Treatment Outcome</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Recommendations for management of cancer-related venous thromboembolism (VTE) in patients already receiving anticoagulant therapy are based on low-quality evidence. This international registry sought to provide more information on outcomes after a breakthrough VTE in relation to anticoagulation strategies.</div>
</front>
</TEI>
<pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">25851122</PMID>
<DateCreated><Year>2015</Year>
<Month>06</Month>
<Day>02</Day>
</DateCreated>
<DateCompleted><Year>2016</Year>
<Month>02</Month>
<Day>25</Day>
</DateCompleted>
<DateRevised><Year>2015</Year>
<Month>06</Month>
<Day>02</Day>
</DateRevised>
<Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1538-7836</ISSN>
<JournalIssue CitedMedium="Internet"><Volume>13</Volume>
<Issue>6</Issue>
<PubDate><Year>2015</Year>
<Month>Jun</Month>
</PubDate>
</JournalIssue>
<Title>Journal of thrombosis and haemostasis : JTH</Title>
<ISOAbbreviation>J. Thromb. Haemost.</ISOAbbreviation>
</Journal>
<ArticleTitle>Recurrent venous thromboembolism in anticoagulated patients with cancer: management and short-term prognosis.</ArticleTitle>
<Pagination><MedlinePgn>1010-8</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1111/jth.12955</ELocationID>
<Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Recommendations for management of cancer-related venous thromboembolism (VTE) in patients already receiving anticoagulant therapy are based on low-quality evidence. This international registry sought to provide more information on outcomes after a breakthrough VTE in relation to anticoagulation strategies.</AbstractText>
<AbstractText Label="METHODS" NlmCategory="METHODS">Patients with cancer and VTE despite anticoagulant therapy were reported to the registry. Data on treatments, VTE events, major bleeding, residual thrombosis symptoms and death were collected for the following 3 months. Breakthrough VTE and subsequent recurrences were objectively verified. Outcomes with different treatment strategies were compared with Cox proportional hazards regression.</AbstractText>
<AbstractText Label="RESULTS" NlmCategory="RESULTS">We registered 212 patients with breakthrough VTE. Of those, 59% had adenocarcinoma and 73% had known metastases. At the time of the breakthrough event, 70% were on low-molecular-weight heparin (LMWH) and 27% on a vitamin K antagonist (VKA); 70% had a therapeutic or supratherapeutic dose. After breakthrough the regimen was: unchanged therapeutic dose in 33%, dose increased in 31%, switched to another drug in 24%; and other management in 11%. During the following 3 months 11% had another VTE, 8% had major bleeding and 27% died. Of the survivors, 74% had residual thrombosis symptoms. Additional VTE recurrence was less common with LMWH than with a VKA (hazard ratio [HR], 0.28; 95% confidence interval [CI], 0.11-0.70) but similar with unchanged or increased anticoagulant intensity (HR, 1.09; 95% CI, 0.45-2.63). The bleeding rate did not increase significantly with dose escalation.</AbstractText>
<AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Morbidity and mortality are high after recurrence of cancer-related VTE despite anticoagulation. Further treatment appears to be more effective with LMWH than with a VKA.</AbstractText>
<CopyrightInformation>© 2015 International Society on Thrombosis and Haemostasis.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Schulman</LastName>
<ForeName>S</ForeName>
<Initials>S</Initials>
<AffiliationInfo><Affiliation>Department of Medicine, McMaster University, Hamilton, ON, Canada.</Affiliation>
</AffiliationInfo>
<AffiliationInfo><Affiliation>Karolinska Institutet, Stockholm, Sweden.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Zondag</LastName>
<ForeName>M</ForeName>
<Initials>M</Initials>
<AffiliationInfo><Affiliation>Department of Medicine, McMaster University, Hamilton, ON, Canada.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Linkins</LastName>
<ForeName>L</ForeName>
<Initials>L</Initials>
<AffiliationInfo><Affiliation>Department of Medicine, McMaster University, Hamilton, ON, Canada.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Pasca</LastName>
<ForeName>S</ForeName>
<Initials>S</Initials>
<AffiliationInfo><Affiliation>Center for Hemorrhagic and Thrombotic Disease, University Hospital of Udine, Udine, Italy.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Cheung</LastName>
<ForeName>Y W</ForeName>
<Initials>YW</Initials>
<AffiliationInfo><Affiliation>Academic Medical Centre, University of Amsterdam, Amsterdam, the Netherlands.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>de Sancho</LastName>
<ForeName>M</ForeName>
<Initials>M</Initials>
<AffiliationInfo><Affiliation>Weill Cornell Medical College, New York, NY, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Gallus</LastName>
<ForeName>A</ForeName>
<Initials>A</Initials>
<AffiliationInfo><Affiliation>Flinders University, Adelaide, SA, Australia.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Lecumberri</LastName>
<ForeName>R</ForeName>
<Initials>R</Initials>
<AffiliationInfo><Affiliation>Hematology Service, University Clinic of Navarra, Pamplona, Spain.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Molnar</LastName>
<ForeName>S</ForeName>
<Initials>S</Initials>
<AffiliationInfo><Affiliation>Oncology and Hematology Department, Sanatorio Allende, Cordoba, Argentina.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Ageno</LastName>
<ForeName>W</ForeName>
<Initials>W</Initials>
<AffiliationInfo><Affiliation>Department of Clinical and Experimental Medicine, University of Insubria, Varese, Italy.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Le Gal</LastName>
<ForeName>G</ForeName>
<Initials>G</Initials>
<Identifier Source="ORCID">http://orcid.org/0000-0002-9253-248X</Identifier>
<AffiliationInfo><Affiliation>Department of Internal Medicine and Chest Diseases, Brest University Hospital, Brest, France.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Falanga</LastName>
<ForeName>A</ForeName>
<Initials>A</Initials>
<AffiliationInfo><Affiliation>Department of Immunohematology and Transfusion Medicine, Hospital Papa Giovanni XXIII, Bergamo, Italy.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Hulegårdh</LastName>
<ForeName>E</ForeName>
<Initials>E</Initials>
<AffiliationInfo><Affiliation>Department of Hematology and Coagulation, Sahlgrenska University Hospital, Gothenburg, Sweden.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Ranta</LastName>
<ForeName>S</ForeName>
<Initials>S</Initials>
<AffiliationInfo><Affiliation>Karolinska Institutet, Stockholm, Sweden.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Kamphuisen</LastName>
<ForeName>P</ForeName>
<Initials>P</Initials>
<AffiliationInfo><Affiliation>Department of Vascular Medicine, University Medical Centre Groningen, University of Groningen, Groningen, the Netherlands.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Debourdeau</LastName>
<ForeName>P</ForeName>
<Initials>P</Initials>
<AffiliationInfo><Affiliation>Oncology Department, Ste Catherine Institute, Avignon, France.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Rigamonti</LastName>
<ForeName>V</ForeName>
<Initials>V</Initials>
<AffiliationInfo><Affiliation>Praxis Bubenberg, Bern, Switzerland.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Ortel</LastName>
<ForeName>T L</ForeName>
<Initials>TL</Initials>
<AffiliationInfo><Affiliation>Division of Hematology, Duke University Medical Center, Durham, NC, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Lee</LastName>
<ForeName>A</ForeName>
<Initials>A</Initials>
<AffiliationInfo><Affiliation>Diamond Health Care Centre, University of British Columbia and Vancouver Coastal Health, Vancouver, BC, Canada.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic"><Year>2015</Year>
<Month>05</Month>
<Day>09</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo><Country>England</Country>
<MedlineTA>J Thromb Haemost</MedlineTA>
<NlmUniqueID>101170508</NlmUniqueID>
<ISSNLinking>1538-7836</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList><Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000925">Anticoagulants</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D006495">Heparin, Low-Molecular-Weight</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>12001-79-5</RegistryNumber>
<NameOfSubstance UI="D014812">Vitamin K</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>5Q7ZVV76EI</RegistryNumber>
<NameOfSubstance UI="D014859">Warfarin</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000925" MajorTopicYN="N">Anticoagulants</DescriptorName>
<QualifierName UI="Q000008" MajorTopicYN="Y">administration & dosage</QualifierName>
<QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D016009" MajorTopicYN="N">Chi-Square Distribution</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D057915" MajorTopicYN="N">Drug Substitution</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006470" MajorTopicYN="N">Hemorrhage</DescriptorName>
<QualifierName UI="Q000139" MajorTopicYN="N">chemically induced</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006495" MajorTopicYN="N">Heparin, Low-Molecular-Weight</DescriptorName>
<QualifierName UI="Q000008" MajorTopicYN="Y">administration & dosage</QualifierName>
<QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D053208" MajorTopicYN="N">Kaplan-Meier Estimate</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D009369" MajorTopicYN="N">Neoplasms</DescriptorName>
<QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName>
<QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName>
<QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName>
<QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D016016" MajorTopicYN="N">Proportional Hazards Models</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D012008" MajorTopicYN="N">Recurrence</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D012042" MajorTopicYN="N">Registries</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D013997" MajorTopicYN="N">Time Factors</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D054556" MajorTopicYN="N">Venous Thromboembolism</DescriptorName>
<QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName>
<QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName>
<QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
<QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName>
<QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D014812" MajorTopicYN="N">Vitamin K</DescriptorName>
<QualifierName UI="Q000037" MajorTopicYN="N">antagonists & inhibitors</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D014859" MajorTopicYN="N">Warfarin</DescriptorName>
<QualifierName UI="Q000008" MajorTopicYN="Y">administration & dosage</QualifierName>
<QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
</MeshHeading>
</MeshHeadingList>
<KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">bleeding</Keyword>
<Keyword MajorTopicYN="N">cancer</Keyword>
<Keyword MajorTopicYN="N">low-molecular-weight heparin</Keyword>
<Keyword MajorTopicYN="N">venous thromboembolism</Keyword>
<Keyword MajorTopicYN="N">warfarin</Keyword>
</KeywordList>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="received"><Year>2014</Year>
<Month>12</Month>
<Day>19</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="accepted"><Year>2015</Year>
<Month>03</Month>
<Day>29</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez"><Year>2015</Year>
<Month>4</Month>
<Day>9</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="pubmed"><Year>2015</Year>
<Month>4</Month>
<Day>9</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>2016</Year>
<Month>2</Month>
<Day>26</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="pubmed">25851122</ArticleId>
<ArticleId IdType="doi">10.1111/jth.12955</ArticleId>
</ArticleIdList>
</PubmedData>
</pubmed>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/PubMed/Corpus

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002D29 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd -nk 002D29 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Asie
   |area=    AustralieFrV1
   |flux=    PubMed
   |étape=   Corpus
   |type=    RBID
   |clé=     pubmed:25851122
   |texte=   Recurrent venous thromboembolism in anticoagulated patients with cancer: management and short-term prognosis.
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/RBID.i   -Sk "pubmed:25851122" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd   \
       | NlmPubMed2Wicri -a AustralieFrV1

This area was generated with Dilib version V0.6.33.
Data generation: Tue Dec 5 10:43:12 2017. Site generation: Tue Mar 5 14:07:20 2024

	Serveur d'exploration sur les relations entre la France et l'Australie
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Serveur d'exploration sur les relations entre la France et l'Australie

Recurrent venous thromboembolism in anticoagulated patients with cancer: management and short-term prognosis.

Recurrent venous thromboembolism in anticoagulated patients with cancer: management and short-term prognosis.

Source :

English descriptors

Abstract

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

Pour générer des pages wiki